{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:31:28Z","timestamp":1771029088343,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006432","name":"Terumo BCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.transci.2025.104251","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:56:40Z","timestamp":1756828600000},"page":"104251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers"],"prefix":"10.1016","volume":"64","author":[{"given":"Nabih","family":"Azar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson J.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Cliquennois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Geske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Henzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamarah","family":"Kent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Poullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsiporah B.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-0720","authenticated-orcid":false,"given":"Matthew","family":"Cawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Waltl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2025.104251_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-Based approach from the writing committee of the American society for apheresis: the ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2025.104251_bib2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.hoc.2022.05.001","article-title":"Evolution of gene therapy, historical perspective","volume":"36","author":"Malech","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.transci.2025.104251_bib3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41409-022-01702-w","article-title":"Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the autoimmune diseases working party (ADWP) of the european society for blood and marrow transplantation (EBMT)","volume":"57","author":"Alexander","year":"2022","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104251_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.12968\/hmed.2019.80.1.33","article-title":"Haematopoietic stem cell transplants: principles and indications","volume":"80","author":"Balassa","year":"2019","journal-title":"Br J Hosp Med"},{"key":"10.1016\/j.transci.2025.104251_bib5","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104251_bib6","first-page":"514","article-title":"Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian expert panel","volume":"21","author":"Leone","year":"2023","journal-title":"Blood Transfus"},{"key":"10.1016\/j.transci.2025.104251_bib7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.transci.2025.104251_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jcyt.2022.02.007","article-title":"Considerations for immune effector cell therapy collections: a White paper from the American society for apheresis","volume":"24","author":"Liu","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.transci.2025.104251_bib9","first-page":"594","article-title":"Updated indications for immune effector cell therapy: 2023 guidelines from the American society for transplantation and cellular therapy","volume":"29","author":"Kanate","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.transci.2025.104251_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.14074","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies: successes, challenges, and opportunities","volume":"112","author":"Ho","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transci.2025.104251_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological malignancies: where are we now and where are we heading for?","volume":"112","author":"Khan","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transci.2025.104251_bib12","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor t cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.transci.2025.104251_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/IJCTM.S104333","article-title":"Spectra Optia\u00ae apheresis system: current insights into clinical risks and benefits","volume":"6","author":"Klink","year":"2018","journal-title":"Int J Clin Transfus Med"},{"key":"10.1016\/j.transci.2025.104251_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41409-024-02248-9","article-title":"Hematopoietic cell transplantation and cellular therapies in Europe 2022. Car-t activity continues to grow; transplant activity has slowed: a report from the EBMT","volume":"59","author":"Passweg","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"10.1016\/j.transci.2025.104251_bib15","first-page":"409.e1","article-title":"Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes","volume":"28","author":"Phelan","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.transci.2025.104251_bib16","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104251_bib17","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104251_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.csbj.2014.08.002","article-title":"Personalized Medicine in hematology \u2014 a landmark from bench to bed","volume":"10","author":"Badalian-Very","year":"2014","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.transci.2025.104251_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000536","article-title":"Precision Medicine in hematology 2021: definitions, tools, perspectives, and open questions","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.transci.2025.104251_bib20","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3390\/curroncol31040143","article-title":"A review of practice-changing therapies in oncology in the era of personalized medicine","volume":"31","author":"Capella","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.transci.2025.104251_bib21","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.transci.2025.104251_bib22","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR t cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.transci.2025.104251_bib23","article-title":"The race to retain healthcare workers: a systematic review on factors that impact retention of nurses and physicians in hospitals","volume":"60","author":"de Vries","year":"2023","journal-title":"Inquiry"},{"key":"10.1016\/j.transci.2025.104251_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300377","article-title":"Determinants of intention to leave among nurses and physicians in a hospital setting during the COVID-19 pandemic: a systematic review and meta-analysis","volume":"19","author":"de Vries","year":"2024","journal-title":"PLOS One"},{"key":"10.1016\/j.transci.2025.104251_bib25","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jcyt.2024.04.001","article-title":"Handling the different requirements for commercial and investigational MNC collections by apheresis","volume":"26","author":"Bobr","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.transci.2025.104251_bib26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcyt.2022.05.002","article-title":"Recommendations for procurement of starting materials by apheresis for advanced therapy medicinal products","volume":"24","author":"Manson","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.transci.2025.104251_bib27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/cells13070586","article-title":"Stem cells collection and mobilization in adult autologous\/allogeneic transplantation: critical points and future challenges","volume":"13","author":"Prisciandaro","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.transci.2025.104251_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/biom14081003","article-title":"Development of VLA4 and CXCR4 antagonists for the mobilization of hematopoietic stem and progenitor cells","volume":"14","author":"Ruminski","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.transci.2025.104251_bib29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41409-023-01957-x","article-title":"A guide to the collection of T-cells by apheresis for ATMP manufacturing-recommendations of the GoCART coalition apheresis working group","volume":"58","author":"Worel","year":"2023","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104251_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2024.101557","article-title":"Celebrating the registration of 9.000 patients treated with CAR t cells in the EBMT registry: collection of real-world data in the context of hematopoietic cellular therapies","volume":"37","author":"Chabannon","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.transci.2025.104251_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13619-023-00173-8","article-title":"Advanced cryopreservation engineering strategies: the critical step to utilize stem cell products","volume":"12","author":"Wang","year":"2023","journal-title":"Cell Regen"},{"key":"10.1016\/j.transci.2025.104251_bib32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41551-018-0246-6","article-title":"Biomanufacturing for clinically advanced cell therapies","volume":"2","author":"Aijaz","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.transci.2025.104251_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fmed.2017.00056","article-title":"Adaptation through collaboration: developing novel platforms to advance the delivery of advanced therapies to patients","volume":"4","author":"Papadaki","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.transci.2025.104251_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jcyt.2020.01.012","article-title":"Variations in novel cellular therapy products manufacturing","volume":"22","author":"Fontaine","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.transci.2025.104251_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41417-019-0157-z","article-title":"Autologous CAR T-cell therapies supply chain: challenges and opportunities?","volume":"27","author":"Papathanasiou","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.transci.2025.104251_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22138","article-title":"A multi-institutional survey of apheresis services among institutions in the United States","volume":"39","author":"Yurtsever","year":"2024","journal-title":"J Clin Apher"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225001892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225001892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:32:31Z","timestamp":1765369951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050225001892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1473050225001892"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104251","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104251"}}